Phase 4
N=100
Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery
Breast Surgery
Bottom Line
View on ClinicalTrials.gov: NCT03549234 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Numeric Rating Scale Pain Scores — 3.0; 0 score on a scale — p=0.0011
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Erector Spinae (single injection) (Drug); Paravertebral (single injection) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Diego
- Primary completion
- May 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Numeric Rating Scale Pain Scores |
3.0; 0 | 0.0011 sig |
| PRIMARY OR and PACU Opioid Consumption |
2.0; 1.4 | 0.0043 sig |
Summary
Following painful surgical procedures of the breast, postoperative analgesia is often provided with a paravertebral nerve block (PVB). For intense, but shorter-duration acute pain, a single-injection of local anesthetic is used with a duration of approximately 12 hours. The PVB has several limitations: it can decrease blood pressure, and very rare-but serious-complications have occurred, including neuraxial injection, neuraxial hematoma, and pleural puncture. An alternative block has been described: the erector spinae plane block. The theoretical benefits include ease of administration since it is a plane superficial to the PVB and therefore easier to identify and target with ultrasound (therefore increasing success rate); and an increased safety margin: there are few anatomic structures in the immediate area which could be injured with the needle; and, the target plane is much further from the intrathecal/epidural space relative to the PVB. Lastly, the plane may be easier to catheterize for continuous peripheral nerve blocks relative to the relatively-small volume PVB.
There are therefore multiple theoretical reasons to prefer the erector spinae plane block. Unfortunately, it remains unknown if the analgesia provided by this new technique is comparable to that provided with the PVB. The investigators therefore propose to compare these two techniques with a randomized, subject-masked, active-controlled, parallel-arm, human subjects clinical trial.
Eligibility Criteria
Inclusion Criteria
- undergoing unilateral or bilateral breast surgery with at least moderate postoperative pain anticipated
- analgesic plan includes a single-injection peripheral nerve block(s)
- age 18 years or older.
Exclusion Criteria
- morbid obesity as defined by a body mass index > 40 (BMI=weight in kg / [height in meters]2)
- renal insufficiency (preoperative creatinine > 1.5 mg/dL)
- chronic opioid use (daily use within the 2 weeks prior to surgery and duration of use > 4 weeks)
- history of opioid abuse
- any comorbidity which results in moderate or severe functional limitation
- inability to communicate with the investigators or hospital staff
- pregnancy
- planned regional analgesic with perineural catheter placement
- incarceration
Data sourced from ClinicalTrials.gov (NCT03549234). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.